Avalon Globocare 2025 Q2 Earnings Deepened Losses Amid Revenue Growth

Avalon Globocare (ALBT) reported its fiscal 2025 Q2 earnings on August 15, 2025, showing revenue growth but significantly wider losses than the prior year. The results fall below expectations due to the company’s continued net loss expansion and negative earnings per share. While the company maintained an optimistic outlook for long-term growth, it did not raise its guidance for the remainder of 2025.

Revenue
Avalon Globocare reported total revenue of $350,406 in Q2 2025, a 6.9% increase from $327,887 in the same period of 2024. This growth was driven entirely by its real property rental segment, which contributed the full amount of the quarter’s revenue.

Earnings/Net Income
The company’s net loss expanded sharply to $13.46 million in Q2 2025, a 531.3% increase from the $2.13 million loss in Q2 2024. On a per-share basis, the loss widened to $6.22, representing a 118.2% increase from the previous year’s loss of $2.85. This marked Avalon Globocare’s ninth consecutive year of losses in the same quarter, underscoring significant financial challenges. The earnings performance was poor, with the company posting a steeply widened loss and negative earnings per share.

Price Action
ALBT’s stock experienced mixed short-term performance, rising 0.92% on the latest trading day but falling 7.20% over the past week and 15.77% month-to-date.

Post-Earnings Price Action Review
A 30-day investment strategy initiated following the earnings report resulted in a -98.55% return, drastically underperforming the 57.28% benchmark return over the same period. The strategy had a negative compound annual growth rate (CAGR) of -79.70% and an excess return of -155.82%, with a Sharpe ratio of -0.37, reflecting poor risk-adjusted performance.

CEO Commentary
Avalon Globocare’s CEO acknowledged the company’s ongoing financial pressures, including a net loss of $13.46 million and an EPS of -$6.22. However, the CEO remained cautiously optimistic, emphasizing investments in R&D and strategic expansion into emerging therapeutic areas. The leadership team is focused on optimizing operational efficiency and advancing key product pipelines to position the company for long-term value.

Guidance
The CEO outlined continued investment in R&D and strategic partnerships to drive future revenue growth, though no specific quantitative guidance was provided for the remainder of 2025. Forward-looking statements included expectations of improved operational performance and key clinical trial milestones by late 2025.

Additional News
The Shanghai Daily recently launched a digital subscription package, offering unlimited access to current and archived articles, as well as real-time downloadable PDFs of the newspaper. While the digital edition is available separately, print subscribers may also opt for a combined print-and-digital package. Subscription rates vary from 1 to 12 months, with digital-only packages starting at RMB 100 (USD 16.99). Online subscribers do not receive print editions, and all digital subscriptions are non-refundable. The website also features exclusive breaking news stories not included in the printed version, enhancing its value for readers seeking real-time updates.